Main Menu
Home > Equity > News Analysis > Hot Pursuit
26 April 2017

Hot Pursuit

Prev Next
25-Apr-2017 (15:15)
Brokerage buy boosts UltraTech Cement
25-Apr-2017 (15:09)
Can Fin Homes moves up on strong Q4 results
25-Apr-2017 (14:44)
M&M moves north on brokerage rating
25-Apr-2017 (14:16)
Alembic Pharma rises after USFDA approvals for drugs
The announcement was made during market hours today, 25 April 2017.

Meanwhile, the S&P BSE Sensex was up 241.56 points, or 0.81% to 29,897.40.

On the BSE, 12,483 shares were traded in the counter so far, compared with average daily volumes of 59,265 shares in the past one quarter. The stock had hit a high of Rs 629 and a low of Rs 605 so far during the day.

The stock had hit a 52-week high of Rs 709.30 on 23 March 2017. The stock had hit a 52-week low of Rs 517.90 on 24 June 2016.

It had underperformed the market over the past one month till 24 April 2017, gaining 0.51% compared with the Sensex's 0.8% rise. The scrip had also under performed the market over the past one quarter, advancing 3.37% as against the Sensex's 8.33% rise.

The large-cap company has equity capital of Rs 37.70 crore. Face value per share is Rs 2.

Alembic Pharmaceuticals announced that it has received final approvals from the United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Olmesartan Medoxomil Tablets, 5mg, 20mg and 40mg and Olmesartan Medoxomil with Hydrochlorothiazide Tablets 20/12.5 mg, 40/12.5 mg and 40/25 mg.

The approved ANDAs are therapeutically equivalent to the reference listed drug products (RLDs) Benicar Tablets 5mg, 20mg and 40 mg and Benicar HCT Tablets, 20/12.5 mg, 40/12.5 mg and 40/25 mg of Daiichi Sankyo Inc. The approved ANDAs are indicated for the treatment of hypertension.

Benicar and Benicar HCT had an estimated annual market size of $1.8 billion in US for twelve months ended 31 December 2016, according to IMS.

Alembic now has a total of 55 ANDA approvals (49 final approvals and 6 tentative approvals) from the USFDA.

On a consolidated basis, net profit of Alembic Pharmaceuticals declined 67.8% to Rs 86.55 crore on 15.9% decline in net sales to Rs 769.86 crore in Q3 December 2016 over Q3 December 2015.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, manufactures and markets generic pharmaceutical products all over the world.


25-Apr-2017 (13:50)
Volumes jump at Welspun Corp counter
25-Apr-2017 (13:48)
Biocon leads gainers in BSE's 'A' group
25-Apr-2017 (13:01)
Eros drops as promoter pares stake
25-Apr-2017 (12:37)
Jubilant Life gets healthier after receiving USFDA nod for drug
25-Apr-2017 (11:55)
Wendt (India) advances after good Q4 earnings
25-Apr-2017 (11:41)
IndusInd Bank nudges higher after opening new branch
Toll Free number: 1800-425-5501 / 1800-103-5501